Document is current
Any future updates will be listed below
-
Authors
Endres, Dominique https://orcid.org/0000-0001-7322-1195
Pollak, Thomas A. https://orcid.org/0000-0002-6171-0810
Bechter, Karl https://orcid.org/0000-0003-4371-2932
Denzel, Dominik
Pitsch, Karoline
Nickel, Kathrin
Runge, Kimon https://orcid.org/0000-0002-0263-4360
Pankratz, Benjamin
Klatzmann, David https://orcid.org/0000-0002-0054-3422
Tamouza, Ryad https://orcid.org/0000-0003-3992-9565
Mallet, Luc https://orcid.org/0000-0001-8061-1167
Leboyer, Marion https://orcid.org/0000-0001-5473-3697
Prüss, Harald https://orcid.org/0000-0002-8283-7976
Voderholzer, Ulrich https://orcid.org/0000-0003-0261-3145
Cunningham, Janet L. https://orcid.org/0000-0001-7876-7779
,
Domschke, Katharina
Tebartz van Elst, Ludger
Schiele, Miriam A.
- License Information
-
More Information
Article History
Received: 23 May 2021
Revised: 9 October 2021
Accepted: 19 October 2021
First Online: 10 January 2022
Competing interests
: KD: Steering Committee Neurosciences, Janssen. LTvE: Advisory boards, lectures, or travel grants within the last three years: Roche, Eli Lilly, Janssen-Cilag, Novartis, Shire, UCB, GSK, Servier, Janssen and Cyberonics. The remaining authors declare no conflicts of interest.
